Top Class Actions’s website and social media posts use affiliate links. If you make a purchase using such links, we may receive a commission, but it will not result in any additional charges to you. Please review our Affiliate Link Disclosure for more information.
Wegovy overview:
- Who: Pharmaceutical company Novo Nordisk announced its weight loss drug Wegovy has the ability to prevent major adverse cardiovascular events such as heart attack or stroke.
- Why: Novo Nordisk said its findings are the result of a five-year trial that compared Wegovy against a placebo during a double-blinded trial of 17,604 adults over the age of 65 with an established cardiovascular disease.
- Where: Wegovy is currently launched in the United States, Denmark, Norway and Germany.
- How to find help: If you are under the age of 75 and experienced diagnosed gastroparesis, stomach paralysis or gastric obstruction from Ozempic/Wegovy/Rybelsus that resulted in an emergency room visit and/or hospital stay, you may qualify to participate in a lawsuit.
The makers of weight loss drug Wegovy announced it has the ability to prevent major adverse cardiovascular events such as heart attack or stroke, per the results of a five-year trial.
Pharmaceutical company Novo Nordisk said it compared the effects of Wegovy with a placebo during a double-blinded trial of 17,604 adults over the age of 65 who were overweight or obese and had an established cardiovascular disease, but with no history of diabetes.
The trial, called “Select,” reached its primary objective of demonstrating a “statistically significant and super reduction” of major adverse cardiovascular events of 20% for trial participants given Wegovy, compared to those given the placebo, according to Novo Nordisk.
“We are very excited about the results from SELECT showing that (Wegovy) reduces the risk of cardiovascular events,” said Martin Holst Lange, executive VP for Development at Novo Nordisk, in a statement.
Novo Nordisk to file for regulatory approvals of a label indication expansion for Wegovy in US and EU
Novo Nordisk said it now expects to file for regulatory approvals of a label indication expansion for Wegovy in both the US and the European Union this year, with the company set to detail the results of the trial at a scientific conference later this year.
The trial was randomized, double-blind, parallel-group, placebo-controlled, and conducted in 41 countries at more than 800 investigator sites, beginning in 2018, according to Novo Nordisk, which has its headquarters in Denmark.
“SELECT is a landmark trial and has demonstrated that (Wegovy) has the potential to change how obesity is regarded and treated,” Holst Lange said.
A one-month supply of Wegovy costs $1,349 per month before insurance, reports CNN Health.
The U.S. Food and Drug Administration (FDA) in June warned consumers not to use generic versions of Wegovy — along with fellow weight loss drug Ozempic — over concerns they are not guaranteed to have the same ingredients as their name-brand versions.
Have you taken the weight loss drug Wegovy? Let us know in the comments!
Don’t Miss Out!
Check out our list of Class Action Lawsuits and Class Action Settlements you may qualify to join!
Read About More Class Action Lawsuits & Class Action Settlements:
Honda, Hyundai, Kia, Subaru vehicle data collection class action lawsuit investigation
May 17, 2024 | Legal News
